

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Algorae Pharmaceuticals Limited (ASX:1AI)
ABN	14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Hainsworth
Date of last notice	5 March 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<u>Indirect 1</u> Union Square Capital Pty Ltd <Endeavor A/C> <u>Indirect 2</u> Cathedral Estate Pty Ltd <Cathedral Super Fund>
Date of change	28 September 2026

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<u>Direct</u> (a) 20,000,000 fully paid ordinary shares; (b) 20,000,000 Performance Rights (AGM 2024); (c) 30,000,000 Performance Rights (AGM 2025); and (d) 4,000,000 Unlisted options exercisable at \$0.014 and expiring on 1/12/2029. <u>Indirect 1</u> Union Square Capital Pty Ltd <Endeavor A/C>, an entity in which Mr Hainsworth is director and controlling shareholder: (a) 5,937,500 fully paid ordinary shares; and (b) 1,125,000 Unlisted options exercisable at \$0.014 and expiring on 1/12/2029. <u>Indirect 2</u> Cathedral Estate Pty Ltd <Cathedral Super Fund>, an entity in which Mr Hainsworth is director and controlling shareholder: Nil
Class	(a) Fully paid ordinary shares (b) Unlisted options
Number acquired	<u>Indirect 2</u> (a) 5,937,500 fully paid ordinary shares (b) 1,125,000 Unlisted options exercisable at \$0.014 and expiring on 1/12/2029.
Number disposed	<u>Indirect 1</u> (a) 5,937,500 fully paid ordinary shares (b) 1,125,000 Unlisted options exercisable at \$0.014 and expiring on 1/12/2029.
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(a) \$89,000 (b) \$3,375

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<u>Direct</u> (a) 20,000,000 fully paid ordinary shares; (b) 20,000,000 Performance Rights (AGM 2024); (c) 30,000,000 Performance Rights (AGM 2025); and (d) 4,000,000 Unlisted options exercisable at \$0.014 and expiring on 1/12/2029. <u>Indirect 1</u> Union Square Capital Pty Ltd <Endeavor A/C>, an entity in which Mr Hainsworth is director and controlling shareholder: Nil <u>Indirect 2</u> Cathedral Estate Pty Ltd <Cathedral Super Fund>, an entity in which Mr Hainsworth is director and controlling shareholder: (a) 5,937,500 fully paid ordinary shares; and (b) 1,125,000 Unlisted options exercisable at \$0.014 and expiring on 1/12/2029.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off-market transfer.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.